Patents by Inventor Jamie David Knight

Jamie David Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11840527
    Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: December 12, 2023
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Karine Fabienne Malagu, Paul Colin Michael Winship, Mark Chambers, Jamie David Knight, Roberta Lanaro
  • Patent number: 11767316
    Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 26, 2023
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Karine Fabienne Malagu, Paul Colin Michael Winship, Jean-Laurent Paparin, Mark Chambers, Jamie David Knight, Roberta Lanaro
  • Publication number: 20210040059
    Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Application
    Filed: February 8, 2019
    Publication date: February 11, 2021
    Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, KARINE FABIENNE MALAGU, PAUL COLIN MICHAEL WINSHIP, JEAN-LAURENT PAPARIN, MARK CHAMBERS, JAMIE DAVID KNIGHT, ROBERTA LANARO
  • Publication number: 20200369655
    Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 26, 2020
    Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, KARINE FABIENNE MALAGU, PAUL COLIN MICHAEL WINSHIP, MARK CHAMBERS, JAMIE DAVID KNIGHT, ROBERTA LANARO
  • Patent number: 9216992
    Abstract: The present invention provides thienopyridine compounds which are potassium channel inhibitors. In another embodiment, the invention provides pharmaceutical compositions comprising thienopyridines. In another embodiment, the invention provides methods of using thienopyridines in the treatment or prevention of cancer, arrhythmias, autoimmune diseases and inflammatory diseases, including gastric cancer, atrial fibrillation, type-2 diabetes mellitus, rheumatoid arthritis, type-1 diabetes, inflammatory bowel disorder and demyelinating disorders such as multiple sclerosis.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: December 22, 2015
    Assignee: Xention Limited
    Inventors: John Ford, David John Madge, Helen Jane Payne, Jamie David Knight
  • Publication number: 20100056565
    Abstract: This invention relates to M3 antagonists of formula (I) wherein R2, R4, R5, R6, W, V, A, D, X, t, u and v are as defined herein; pharmaceutical compositions containing them; methods for their preparation; and their use in the treatment of diseases where enhanced M3 receptor activation is implicated.
    Type: Application
    Filed: February 14, 2008
    Publication date: March 4, 2010
    Applicant: ARGENTA DISCOVERY LIMITED
    Inventors: Barbara Giuseppina Avitabile, Harry Finch, Jamie David Knight, Alan John Nadin, Nicholas Charles Ray